Purple Biotech (PPBT) Free Cash Flow (2017 - 2026)

Purple Biotech (PPBT) has 10 years of Free Cash Flow data on file, last reported at -$3.1 million in Q1 2026.

• On a quarterly basis, Free Cash Flow fell 57.79% year-over-year to -$3.1 million in Q1 2026; TTM through Mar 2026 was -$6.8 million, a 39.63% increase from a year earlier, with the FY2025 full-year figure at -$5.7 million, up 60.61% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$3.1 million, down from -$1.1 million in the prior quarter.
• Over the last five years, Free Cash Flow for PPBT reached as high as -$1.1 million in Q3 2025 and fell as low as -$6.1 million in Q1 2023.
• Historically, Free Cash Flow has averaged -$3.5 million across 5 years, with a median of -$3.7 million in 2023.
• Across the five-year window, Free Cash Flow jumped 67.62% in 2025 and sank 57.79% in 2026, its largest moves.
• Year by year, Free Cash Flow stood at -$4.3 million in 2022, then slipped by 16.92% to -$5.0 million in 2023, then surged by 59.62% to -$2.0 million in 2024, then soared by 47.02% to -$1.1 million in 2025, then sank by 192.5% to -$3.1 million in 2026.
• Per Business Quant data, the three most recent Free Cash Flow figures were -$3.1 million in Q1 2026, -$1.1 million in Q4 2025, and -$1.1 million in Q3 2025.